NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 270 filers reported holding NEKTAR THERAPEUTICS in Q4 2017. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $111,224 | +44.4% | 89,698 | +8.8% | 0.00% | – |
| Q1 2024 | $77,008 | +20.9% | 82,434 | -26.9% | 0.00% | – |
| Q4 2023 | $63,713 | -32.6% | 112,769 | -28.9% | 0.00% | – |
| Q3 2023 | $94,509 | +2.4% | 158,680 | -1.1% | 0.00% | – |
| Q2 2023 | $92,268 | -18.2% | 160,413 | 0.0% | 0.00% | – |
| Q1 2023 | $112,753 | -69.4% | 160,413 | -1.6% | 0.00% | -100.0% |
| Q4 2022 | $368,584 | +39.6% | 163,091 | +96.3% | 0.00% | 0.0% |
| Q3 2022 | $264,000 | +1930.8% | 83,081 | +2290.1% | 0.00% | – |
| Q2 2022 | $13,000 | -79.7% | 3,476 | -71.5% | 0.00% | – |
| Q1 2022 | $64,000 | -66.8% | 12,214 | -14.8% | 0.00% | – |
| Q4 2021 | $193,000 | -43.7% | 14,332 | -25.1% | 0.00% | -100.0% |
| Q3 2021 | $343,000 | -2.3% | 19,136 | -6.7% | 0.00% | 0.0% |
| Q2 2021 | $351,000 | -42.7% | 20,514 | -33.2% | 0.00% | 0.0% |
| Q1 2021 | $613,000 | -19.6% | 30,729 | -31.1% | 0.00% | -50.0% |
| Q4 2020 | $762,000 | +0.4% | 44,611 | -2.7% | 0.00% | 0.0% |
| Q3 2020 | $759,000 | -35.2% | 45,856 | -9.5% | 0.00% | -33.3% |
| Q2 2020 | $1,172,000 | +6068.4% | 50,675 | +4592.1% | 0.00% | – |
| Q1 2020 | $19,000 | +216.7% | 1,080 | +239.6% | 0.00% | – |
| Q4 2019 | $6,000 | -91.4% | 318 | -91.8% | 0.00% | – |
| Q3 2019 | $70,000 | -48.5% | 3,893 | 0.0% | 0.00% | – |
| Q2 2019 | $136,000 | +6.2% | 3,893 | 0.0% | 0.00% | – |
| Q1 2019 | $128,000 | +6.7% | 3,893 | +8.9% | 0.00% | – |
| Q4 2018 | $120,000 | -60.7% | 3,575 | -28.8% | 0.00% | -100.0% |
| Q3 2018 | $305,000 | -87.0% | 5,018 | -89.5% | 0.00% | -80.0% |
| Q2 2018 | $2,339,000 | -67.8% | 47,934 | -30.0% | 0.01% | -58.3% |
| Q1 2018 | $7,259,000 | +4.9% | 68,449 | -40.2% | 0.01% | 0.0% |
| Q4 2017 | $6,922,000 | +127.2% | 114,416 | -9.9% | 0.01% | +140.0% |
| Q3 2017 | $3,046,000 | +17.8% | 126,961 | -4.0% | 0.01% | 0.0% |
| Q2 2017 | $2,585,000 | +21.1% | 132,207 | +45.3% | 0.01% | +25.0% |
| Q1 2017 | $2,135,000 | +118.1% | 90,965 | +13.3% | 0.00% | +100.0% |
| Q4 2016 | $979,000 | – | 80,290 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
| MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
| Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
| Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
| Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
| Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
| CM Management, LLC | 35,000 | $595,000 | 0.55% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
| RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
| Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |